New patent expiration for Gilead Sciences drug ODEFSEY – DrugPatentWatch
Annual Drug Patent Expiration for ODEFSEY
Odefsey is a drug marketed by Gilead Sciences Inc and included in one NDA. It is available from a single supplier. There are seven patents protecting this drug.
Drug patent litigation for ODEFSEY.
This drug has two hundred and fifty-four patent family members in forty-seven countries.
The generic ingredient in ODEFSEY is emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. One registered supplier for this compound. Additional details are available on emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published at the time of expiration of a new patent for the Gilead Sciences drug ODEFSEY
